CVRx, Inc. $CVRX Shares Purchased by Parkman Healthcare Partners LLC

Key Points

• Parkman Healthcare Partners LLC increased its stake in CVRx, Inc. by 33.5%, owning about 1,229,522 shares valued at $15 million, making up 1.8% of its portfolio.
• The stock has seen mixed analyst ratings, with one strong buy, five buy ratings, and an average target price of $14.00.
• CVRx's latest earnings report indicated a loss of ($0.57) per share, missing estimates, but exceeding revenue expectations with $13.59 million reported.

Parkman Healthcare Partners LLC boosted its holdings in CVRx, Inc. (NASDAQ:CVRX - Free Report) by 33.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 1,229,522 shares of the company's stock after buying an additional 308,348 shares during the quarter. CVRx makes up about 1.8% of Parkman Healthcare Partners LLC's holdings, making the stock its 19th largest position. Parkman Healthcare Partners LLC owned 4.72% of CVRx worth $15,037,000 at the end of the most recent quarter.

Several other large investors have also recently bought and sold shares of the business. Cubist Systematic Strategies LLC increased its holdings in CVRx by 48.1% in the first quarter. Cubist Systematic Strategies LLC now owns 59,105 shares of the company's stock valued at $723,000 after buying an additional 19,183 shares during the last quarter. AlphaQuest LLC increased its holdings in CVRx by 725.4% in the first quarter. AlphaQuest LLC now owns 6,108 shares of the company's stock valued at $75,000 after buying an additional 5,368 shares during the last quarter. Lord Abbett & CO. LLC purchased a new position in CVRx in the first quarter valued at $4,852,000. Russell Investments Group Ltd. increased its holdings in CVRx by 70.1% in the first quarter. Russell Investments Group Ltd. now owns 61,133 shares of the company's stock valued at $748,000 after buying an additional 25,194 shares during the last quarter. Finally, Informed Momentum Co LLC purchased a new stake in shares of CVRx during the 1st quarter worth approximately $683,000. Hedge funds and other institutional investors own 75.27% of the company's stock.

CVRx Stock Performance

NASDAQ CVRX traded up $0.11 during trading hours on Tuesday, hitting $8.06. The company had a trading volume of 101,615 shares, compared to its average volume of 187,069. The business has a 50 day moving average of $7.55 and a 200-day moving average of $8.07. CVRx, Inc. has a 1-year low of $4.30 and a 1-year high of $18.55. The company has a debt-to-equity ratio of 0.85, a quick ratio of 10.78 and a current ratio of 11.99. The company has a market cap of $210.77 million, a PE ratio of -3.84 and a beta of 1.26.

CVRx (NASDAQ:CVRX - Get Free Report) last announced its earnings results on Monday, August 4th. The company reported ($0.57) EPS for the quarter, missing analysts' consensus estimates of ($0.52) by ($0.05). The business had revenue of $13.59 million during the quarter, compared to analysts' expectations of $13.22 million. CVRx had a negative net margin of 95.61% and a negative return on equity of 79.31%. CVRx has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. As a group, equities research analysts expect that CVRx, Inc. will post -1.91 EPS for the current year.

Analyst Ratings Changes

Several analysts have recently weighed in on CVRX shares. William Blair upgraded shares of CVRx to a "strong-buy" rating in a research report on Monday, July 7th. Cantor Fitzgerald restated an "overweight" rating and issued a $11.00 price objective on shares of CVRx in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of "Moderate Buy" and an average price target of $14.00.

CVRx Profile

CVRx, Inc, a commercial-stage medical device company, focuses on developing, manufacturing, and commercializing neuromodulation solutions for patients with cardiovascular diseases. The company offers Barostim, a neuromodulation device indicated to improve symptoms for patients with heart failure with reduced ejection fraction or systolic heart failure.